Stoke Therapeutics director granted 17,786 options
Stoke Therapeutics director Arthur Tzianabos received a grant of options for 17,786 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Stoke Therapeutics director Arthur Tzianabos received a grant of options for 17,786 shares of common stock. The Director Stock Option has an exercise price of $29.46 per share and expires on June 2, 2036. It will vest in full on the earlier of June 3, 2027 or the company’s next annual stockholder meeting, subject to his continued service.
Insider Trade Summary
Grant/Award: 17,786 shares
Grant/Award
1 txn
Insider
TZIANABOS ARTHUR
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (Right to Buy) | 17,786 | $0.00 | $0.00 |
Holdings After Transaction:
Director Stock Option (Right to Buy) — 17,786 contracts (Direct)
Footnotes (1)
- F1. The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.
Key Figures
Option grant size: 17,786 options
Exercise price: $29.46 per share
Expiration date: June 2, 2036
+2 more
5 metrics
Option grant size
17,786 options
Director Stock Option grant on June 3, 2026
Exercise price
$29.46 per share
Strike price for Director Stock Option
Expiration date
June 2, 2036
Director Stock Option term end
Post-grant derivative holdings
17,786 options
Total derivative securities following transaction
Vesting trigger date
June 3, 2027 or next annual meeting
Full vesting contingent on continued service
Key Terms
Director Stock Option, exercise price, expiration date, vesting
4 terms
Director Stock Option financial
"security_title: "Director Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "29.4600" per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-02T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"The option shall vest in full on the earlier of June 3, 2027 or the date of the issuer's next annual meeting"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Stoke Therapeutics (STOK) report for Arthur Tzianabos?
Stoke Therapeutics reported that director Arthur Tzianabos received a grant of stock options covering 17,786 shares of common stock. These options are part of his director compensation and give him the right to buy shares at a fixed exercise price if they vest.
What is the exercise price of the new Arthur Tzianabos options at Stoke Therapeutics (STOK)?
The new director stock option granted to Arthur Tzianabos has an exercise price of $29.46 per share. This is the fixed price at which he can purchase common stock if he exercises the option after it vests and before expiration.
When do Arthur Tzianabos’s newly granted Stoke Therapeutics (STOK) options vest?
The options granted to Arthur Tzianabos vest in full on the earlier of June 3, 2027, or the date of Stoke Therapeutics’ next annual stockholder meeting. Vesting is conditioned on his continued service to the company through that vesting date.
What is the expiration date of Arthur Tzianabos’s new options at Stoke Therapeutics (STOK)?
Arthur Tzianabos’s director stock option expires on June 2, 2036. After this expiration date, he can no longer exercise the option to purchase shares, even if it has vested and was not previously exercised during its term.
How many options does Arthur Tzianabos hold in Stoke Therapeutics (STOK) after this grant?
Following this grant, Arthur Tzianabos holds 17,786 derivative securities in the form of director stock options. This total equals the number of options granted in the transaction, reflecting his full reported option position after the award.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates